Moving Diabetic Retinopathy Treatment Forward by Early Intervention to Improve Long-term Outcomes

Author(s)/Faculty: Peter K. Kaiser, MD; Jorge A. Fortun, MD; Nancy M. Holekamp, MD
Release Date: 7/2/2021Expiration Date: 7/1/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: LectureProvider:
Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases and offers many patients delayed or arrested disease progression and the possibility of regaining lost vision. The effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) therapy in treating diabetic retinopathy (DR) has spurred further research into outcomes of treatment regimens using this approach, yet these options remain underutilized for patients with DR, especially at early stages of disease. Accordingly, retina specialists need education on the latest advances regarding the optimal use of anti-VEGF treatments for patients with DR, how to use them in practice, and how treatment may improve long-term patient outcomes. In this CME activity, experts in the field evaluate new findings pertaining to the optimization of treatment injection protocols and management of patients with proliferative and non-proliferative DR as well as assess treatment regimens for their ability to achieve regression of DR.